A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Trial in Healthy Adults to Evaluate the Safety, Tolerability, and PK of MK-7762
Latest Information Update: 29 Jul 2024
At a glance
- Drugs MK 7762 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; First in man
Most Recent Events
- 26 Jul 2024 Status changed from recruiting to completed.
- 21 May 2024 Planned End Date changed from 6 Apr 2024 to 16 Oct 2024.
- 21 May 2024 Planned primary completion date changed from 1 Apr 2024 to 16 Oct 2024.